March 10, 2023Open Access

Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN)

Structured PICO

Does prasugrel monotherapy provide a safe and feasible alternative to traditional DAPT in low-risk Japanese patients with CCS undergoing PCI?

Population

Selected low-risk Japanese patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) with biodegradable-polymer platinum-chromium everolimus eluting stent

Intervention

Prasugrel monotherapy

Outcome

Safety and feasibilitysafety

Prasugrel monotherapy may be a safe 'aspirin-free' alternative to traditional DAPT following PCI in low-risk patients with chronic coronary syndrome.

Abstract

This pilot study showed the safety and feasibility of prasugrel monotherapy in selected low-risk Japanese patients with CCS. This "aspirin-free" strategy may be a safe alternative to traditional DAPT following PCI.

Perguntar à IA

Bookmark

View Full Paper